10:38 AM EST, 02/05/2025 (MT Newswires) -- Revance Therapeutics ( RVNC ) and Crown Laboratories said Wednesday that the tender offer to buy all of Revance's outstanding shares at $3.65 per share expired on Tuesday, without being extended.

The companies said that as of the expiration, nearly 86.2 million, or 82% of the total, were validly tendered and not withdrawn. Since all conditions have been met, Crown and its affiliate, Reba Merger Sub will accept and pay for all validly tendered shares.

The acquisition is set to close on Thursday as per the terms of the agreement.

Price: 3.66, Change: +0.01, Percent Change: +0.41